-

12:41:26 PM

LIVE Real Time IMAB Stock Market News

IMAB - I-Mab

04/14/21 8:30 AM

Nasdaq : IMAB

I-Mab Announces Selected Poster Presentation of CD73 Antibody Uliledlimab at American Society of Clinical Oncology (ASCO) 2021 Annual Meeting

I-Mab (the "Company") (Nasdaq: IMAB), a clinical-stage biopharmaceutical company committed to the discovery, development and commercialization of novel biologics, today announced that its abstract on proprietary and highly

RHEA-AI

neutral

04/06/21 8:00 AM

Nasdaq : IMAB

I-Mab and ABL Bio Announce First Patient Dosed in Phase 1 Trial of Bispecific Antibody TJ-L14B/ABL503 in Patients with Advanced or Metastatic Solid Tumors

I-Mab (the "Company") (Nasdaq: IMAB), a clinical-stage biopharmaceutical company committed to the discovery, development and commercialization of novel biologics, and ABL Bio, Inc. (Kosdaq:298380,

RHEA-AI

neutral

03/31/21 8:00 AM

Nasdaq : IMAB

I-Mab Announces Upcoming Participation at April Conferences

I-Mab (the "Company") (Nasdaq: IMAB), a clinical stage biopharmaceutical company committed to the discovery, development and commercialization of novel biologic, today announced its participation in the following

RHEA-AI

neutral

03/30/21 8:00 AM

Nasdaq : IMAB

I-Mab and ABL Bio Receive US FDA Approval to Initiate Phase 1 Trial of Bispecific Antibody TJ-CD4B/ABL111 in Patients with Advanced or Metastatic Solid Tumors

I-Mab (the "Company") (Nasdaq: IMAB), a clinical-stage biopharmaceutical company committed to the development of novel biologics, and ABL Bio, Inc. (Kosdaq:298380, hereafter "ABL"), a South Korean biotech specializing in

RHEA-AI

very positive

03/29/21 7:00 AM

Nasdaq : IMAB

I-Mab Reports Financial Results for Full Year of 2020 and Provides Business Updates

18 significant clinical milestones achieved since the Company's IPO in January 2020, with multiple important data readouts for lemzoparlimab (TJC4), uliledlimab (TJD5) and other clinical assets expected in 2021 New drug application (NDA) submission for felzartamab (TJ202) CD38 antibody for

RHEA-AI

positive

03/24/21 8:00 AM

Nasdaq : IMAB

I-Mab to Host 2021 R&D Day

I-Mab (the "Company") (Nasdaq: IMAB), a clinical stage biopharmaceutical company committed to the discovery,

RHEA-AI

neutral

03/19/21 4:20 PM

Nasdaq : IMAB

I-Mab Files Prospectus Supplement for Shelf Registration for Hillhouse

I-Mab (the "Company") (Nasdaq: IMAB), a clinical stage biopharmaceutical company committed to the discovery, development and commercialization of novel biologics, today filed a prospectus supplement with the Securities and

RHEA-AI

neutral

03/11/21 8:00 AM

Nasdaq : IMAB

I-Mab To Present Differentiated Mechanism of Action and Preclinical Data for Anti-CD73 Antibody Uliledlimab at 2021 American Association for Cancer Research Annual Meeting

I-Mab (the "Company") (NASDAQ: IMAB), a clinical stage biopharmaceutical company committed to the discovery, development and commercialization of novel or highly differentiated biologics, today announced that a poster

RHEA-AI

neutral

03/10/21 8:00 AM

Nasdaq : IMAB

I-Mab Launches Discovery Initiative to Expand Transformational Immuno-Oncology Pipeline

- New Initiative is part of I-Mab's long-term strategy to drive innovation and scientific leadership in immuno-oncology - New collaborations signed will allow I-Mab access to cutting edge technology platforms to develop novel drug molecules - I-Mab continues to focus on delivering on key clinical

RHEA-AI

positive

03/03/21 8:00 AM

Nasdaq : IMAB

I-Mab to Report Financial Results for the Full Year 2020 and Provide Corporate Update on March 29, 2021

I-Mab (the "Company") (Nasdaq: IMAB), a clinical stage biopharmaceutical company committed to the discovery, development and commercialization of novel biologics, today announced that it will report financial results for the full year

RHEA-AI

neutral